Nu Skin Enterprises, Inc. (NYSE:NUS) Lifted to Buy at Zacks Investment Research
Zacks Investment Research upgraded shares of Nu Skin Enterprises, Inc. (NYSE:NUS) from a hold rating to a buy rating in a report released on Wednesday. They currently have $70.00 price objective on the stock.
According to Zacks, “Nu Skin is a premier anti-aging company. The company’s anti-aging products feature the ageLOC line of products including ageLOC Tru Face Essence Ultra firming serum, the ageLOC TR90 weight management and body shaping system, ageLOC R2 nutritional supplement, and ageLOC Transformation daily skin care system. “
Other analysts also recently issued reports about the company. Deutsche Bank AG increased their price objective on Nu Skin Enterprises from $63.00 to $66.00 and gave the company a buy rating in a report on Wednesday, June 21st. Bank of America Corporation increased their price target on Nu Skin Enterprises from $53.00 to $57.00 and gave the stock an underperform rating in a report on Monday, July 10th. Sidoti downgraded Nu Skin Enterprises from a buy rating to a neutral rating and set a $59.00 price target for the company. in a report on Wednesday, April 26th. Pivotal Research reiterated a buy rating and set a $65.00 price target on shares of Nu Skin Enterprises in a report on Thursday, May 4th. Finally, ValuEngine upgraded Nu Skin Enterprises from a hold rating to a buy rating in a report on Friday, June 2nd. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company’s stock. Nu Skin Enterprises presently has an average rating of Hold and a consensus target price of $62.25.
Shares of Nu Skin Enterprises (NYSE:NUS) traded down 0.24% during midday trading on Wednesday, hitting $62.91. The company had a trading volume of 122,006 shares. Nu Skin Enterprises has a one year low of $46.35 and a one year high of $66.04. The stock has a market capitalization of $3.32 billion, a price-to-earnings ratio of 20.88 and a beta of 1.31. The stock’s 50-day moving average price is $58.20 and its 200-day moving average price is $53.72.
Nu Skin Enterprises (NYSE:NUS) last posted its quarterly earnings data on Wednesday, May 3rd. The company reported $0.51 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.50 by $0.01. The business had revenue of $499.10 million during the quarter, compared to the consensus estimate of $493.65 million. Nu Skin Enterprises had a return on equity of 23.45% and a net margin of 7.48%. Nu Skin Enterprises’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.42 earnings per share. Analysts predict that Nu Skin Enterprises will post $3.12 EPS for the current year.
In other news, General Counsel D Matthew Dorny sold 8,000 shares of the firm’s stock in a transaction dated Thursday, May 11th. The stock was sold at an average price of $58.32, for a total value of $466,560.00. Following the completion of the sale, the general counsel now directly owns 53,730 shares in the company, valued at approximately $3,133,533.60. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Over the last 90 days, insiders sold 24,250 shares of company stock valued at $1,436,770. 5.20% of the stock is currently owned by company insiders.
A number of institutional investors have recently made changes to their positions in the stock. BlackRock Inc. boosted its position in shares of Nu Skin Enterprises by 21,593.4% in the first quarter. BlackRock Inc. now owns 6,683,531 shares of the company’s stock valued at $371,201,000 after buying an additional 6,652,722 shares during the last quarter. Schroder Investment Management Group boosted its position in shares of Nu Skin Enterprises by 139.4% in the first quarter. Schroder Investment Management Group now owns 1,711,619 shares of the company’s stock valued at $94,687,000 after buying an additional 996,731 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Nu Skin Enterprises by 11.8% in the first quarter. Vanguard Group Inc. now owns 6,011,632 shares of the company’s stock valued at $333,887,000 after buying an additional 634,951 shares during the last quarter. State Street Corp boosted its position in shares of Nu Skin Enterprises by 76.7% in the first quarter. State Street Corp now owns 1,416,873 shares of the company’s stock valued at $78,695,000 after buying an additional 614,817 shares during the last quarter. Finally, Norges Bank acquired a new position in shares of Nu Skin Enterprises during the fourth quarter valued at $27,260,000. 85.51% of the stock is currently owned by institutional investors and hedge funds.
About Nu Skin Enterprises
Nu Skin Enterprises, Inc is a direct selling company that develops and distributes personal care products and nutritional supplements, and a range of other products and services. The Company offers anti-aging personal care products and nutritional supplements under its Nu Skin and Pharmanex brands. The Nu Skin brand offers a range of products, including ageLOC Me customized skin care system, ageLOC Spa systems and ageLOC Transformation anti-aging skin care system.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nu Skin Enterprises Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nu Skin Enterprises Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.